12 Health Care Stocks Moving In Monday's After-Market Session
GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to
Greenwich LifeSciences (GLSI.US): The 2023 Q4 earnings report achieved revenue of $0, previous value of $0; earnings per share were -$0.21, previous value was -$0.22, and expected value was -$0.20.
Greenwich LifeSciences (GLSI.US): The 2023 Q4 earnings report achieved revenue of $0, previous value of $0; earnings per share were -$0.21, previous value was -$0.22, and expected value was -$0.20.
Insiders Are Piling Into These 10 Healthcare Stocks in 2024
Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$57,240 in Common Stock
$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 3,000 shares of Common Stock on Apr 1, 2024 at an average price of $19.08 for a total value of $57,240.Source: Announcement Wha
Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$49,950 in Common Stocks
$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 2,500 shares of Common Stocks on Mar 22, 2024 at an average price of $19.98 for a total value of $49,950.Source: Announcement W
Insiders Buying Greenwich LifeSciences And 2 Other Stocks
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view t
Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$26,520 in Common Stocks
$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 1,500 shares of Common Stocks on Mar 20, 2024 at an average price of $17.68 for a total value of $26,520.Source: Announcement W
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
Insiders Continue to Buy Greenwich LifeSciences, Inc. (NASDAQ:GLSI) and Now Own 55% Shares
Key Insights Insiders appear to have a vested interest in Greenwich LifeSciences' growth, as seen by their sizeable ownership The top 4 shareholders own 52% of the company Insiders have bought re
Greenwich LifeSciences Partners With GEICAM in Spain & Conducts First Site Initiation Visits in Europe
STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,
(SEC Amendment) Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$43,715 in Common Stocks
$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 3,500 shares of Common Stocks on Mar 5, 2024 at an average price of $12.49 for a total value of $43,715.Source: Announcement Wh
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing
Snehal Patel, 10% Owner, Director, CEO and CFO, on March 05, 2024, executed a purchase for 30,500 shares in Greenwich Lifesciences (GLSI) for $380,945. Following the Form 4 filing with the SEC, Patel
Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$53,423 in Common Stocks
$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 4,100 shares of Common Stocks on Mar 4, 2024 at an average price of $13.03 for a total value of $53,423.Source: Announcement Wh
HC Wainwright & Co. Reiterates Buy on Greenwich LifeSciences, Maintains $36 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences with a Buy and maintains $36 price target.
Expanding Horizons: Bullish Buy Rating as Greenwich LifeSciences's Breast Cancer Trial Goes Pan-European
Greenwich LifeSciences Stock Jumps 8% on Phase 3 Study Expansion
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand Into Five Largest European Countries
STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01,
Greenwich LifeSciences Secures Approval to Expand GLSI-100's Phase 3 Trial to Europe
Greenwich LifeSciences (GLSI) shares were up more than 7% in recent Thursday trading after the company said the European Medicines Agency has approved the expansion of its phase 3 trial evaluating GLS
Greenwich Lifesciences Announces Acceptance for Flamingo-01 Trial by EMA
Greenwich LifeSciences Gains EMA Nod for Breast Cancer Prevention Trial Expansion
No Data